CRDF

4.23

7.24% -0.33

Pre-mercato: 4.24 0.010 +0.24%

Cardiff Oncology Inc (CRDF)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$4.56

Aprire:

$4.53

Volume 24 ore:

1.07M

Relative Volume:

0.54

Capitalizzazione di mercato:

$281.40M

Reddito:

$488.00K

Utile/perdita netta:

$-41.44M

Rapporto P/E:

-4.5484

EPS:

-0.93

Flusso di cassa netto:

$-31.47M

1 W Prestazione:

-0.24%

1M Prestazione:

+24.05%

6M Prestazione:

+76.99%

1 anno Prestazione:

+153.29%

Intervallo 1D:

$4.16

$4.60

Intervallo di 1 settimana:

$4.12

$4.99

Portata 52W:

$1.66

$6.42

Cardiff Oncology Inc Stock (CRDF) Company Profile

Nome

Cardiff Oncology Inc

Settore

Healthcare (1167)

Industria

Biotechnology (674)

Telefono

858-952-7570

Indirizzo

11055 FLINTKOTE AVENUE, SAN DIEGO, CA

Dipendente

Cinguettio

@cardiffoncology

Prossima data di guadagno

2024-10-31

Ultimi documenti SEC

CRDF's Discussions on Twitter

Confronta CRDF con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CRDF Cardiff Oncology Inc	4.23	281.40M	488.00K	-41.44M	-31.47M	-0.93
VRTX Vertex Pharmaceuticals Inc	480.35	123.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	723.47	79.09B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	624.94	37.97B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.20	31.74B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	259.70	27.71B	3.32B	-860.46M	-1.04B	-8.32

Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-09-06	Iniziato	Craig Hallum	Buy
2022-01-05	Iniziato	William Blair	Outperform
2021-12-08	Iniziato	Robert W. Baird	Outperform
2021-08-09	Ripresa	Maxim Group	Buy
2020-10-22	Iniziato	H.C. Wainwright	Buy
2020-10-08	Iniziato	Piper Sandler	Overweight

Mostra tutto

Cardiff Oncology Inc Borsa (CRDF) Ultime notizie

Feb 25, 2025

Cardiff Oncology Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView

Feb 25, 2025

Feb 24, 2025

Cardiff Oncology to Present at Upcoming Investor Conferences - The Manila Times

Feb 24, 2025

Can Cardiff Oncology's New Colorectal Cancer Approach Transform Treatment? CEO to Reveal Strategy - StockTitan

Feb 24, 2025

Feb 23, 2025

Critical Contrast: Cardiff Oncology (NASDAQ:CRDF) versus Vir Biotechnology (NASDAQ:VIR) - Defense World

Feb 23, 2025

Feb 22, 2025

Cardiff Oncology (CRDF) to Release Earnings on Thursday - Defense World

Feb 22, 2025

Feb 20, 2025

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update - The Manila Times

Feb 20, 2025

Can Cardiff Oncology's Q4 Earnings Reveal New Cancer Drug Progress? - StockTitan

Feb 20, 2025

Bullish Cardiff Oncology Insiders Rewarded As Their Investment Rises To US$1.81m - Simply Wall St

Feb 20, 2025

Feb 19, 2025

Cardiff Oncology, Inc. (NASDAQ:CRDF) Sees Significant Growth in Short Interest - MarketBeat

Feb 19, 2025

Taking on analysts’ expectations and winning: Cardiff Oncology Inc (CRDF) - SETE News

Feb 19, 2025

Feb 18, 2025

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib (NASDAQ:CRDF) - Seeking Alpha

Feb 18, 2025

Cardiff Oncology, Inc. (NASDAQ:CRDF) Sees Significant Increase in Short Interest - Defense World

Feb 18, 2025

Feb 14, 2025

SG Americas Securities LLC Sells 6,103 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World

Feb 14, 2025

Feb 13, 2025

Compass Therapeutics (NASDAQ:CMPX) & Cardiff Oncology (NASDAQ:CRDF) Critical Review - Defense World

Feb 13, 2025

Feb 12, 2025